Medicare premiums won't be lowered this year; how long until there's Paxlovid resistance?

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by         The newsletter will be on hiatus for the Memorial Day holiday Monday, but will be back in your inbox on Tuesday. Biden administration won't lower seniors' Medicare premiums this year, despite changes to coverage of new Alzheimer's drug By Rachel Cohrs Al Drago-Pool/Getty Images The administration will not lower Medicare premiums this year, even though costs spiked based on inflated financial projections for Aduhelm. Read More Coronavirus hasn't developed resistance to Paxlovid. How long can that last? By Jason Mast Adobe Resistance is the hobgoblin of antiviral medicine, even with antivirals as effective as Paxlovid. Read More STAT+: ViiV will make it easier for generic companies to copy its HIV prevention shot, but it's not clear when By Ed Silverman C. Goldsmith, P. Feorino, E. L. Palmer, W. R. McManus/CDC This is a long overdue step, said Jessica Burry of Doctors Without Borders. But it will still take years before generics are available. Read More Sponsor content by Janssen Research & Development, LLC. Pioneering precision in neuroscience We are living in an era of precision medicine, where scientific innovations have improved drug targeting across various patient populations and most therapeutic areas. However, within neuroscience, the growing unmet needs, everchanging landscape, and complex biology of neurological and neuropsychiatric disorders have made precision medicine difficult to apply. At Janssen, researchers aim to lead the neuroscience revolution to reduce the burden and disability caused by neuropsychiatric, neurological, and neurodegenerative diseases. Read the article here. STAT+: Key Senate committee proposes a council to ensure FDA better coordinates on accelerated approvals By Lev Facher Jessica Rinaldi/The Boston Globe Key senators want to create a council meant to help the FDA sidestep some of the issues that plagued its approval of Aduhelm. Read More An emergency doctor and parent sorts through Covid vaccine options for kids under 5 By Adam Feuerstein and Meg Tirrell JEFF KOWALSKY/AFP via Getty Images STAT sat down Jeremy Faust, an emergency physician and a dad of a kid under 5 who's sorting through all of this himself. Read More STAT+: The World Health Assembly moves to bolster clinical trials, but some say it falls short By Ed Silverman “There were some missed opportunities,” said Francisco Viegas, a medical policy advisor to Doctors Without Borders. Read More STAT+: Up and down the ladder: The latest comings and goings By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More Friday, May 27, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser